IN8bio, Inc. (INAB)
INAB Stock Price Chart
Explore IN8bio, Inc. interactive price chart. Choose custom timeframes to analyze INAB price movements and trends.
INAB Company Profile
Discover essential business fundamentals and corporate details for IN8bio, Inc. (INAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jul 2021
Employees
18.00
Website
https://in8bio.comCEO
Tai-Wei
Description
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
INAB Financial Timeline
Browse a chronological timeline of IN8bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.34.
Earnings released on 7 May 2026
EPS came in at -$0.26 surpassing the estimated -$0.59 by +55.93%.
Earnings released on 12 Mar 2026
EPS came in at -$0.26 falling short of the estimated -$0.18 by -44.44%.
Earnings released on 6 Nov 2025
EPS came in at -$0.85 surpassing the estimated -$1.20 by +29.17%.
Earnings released on 7 Aug 2025
EPS came in at -$1.24 surpassing the estimated -$1.50 by +17.33%.
Stock split effective on 6 Jun 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2025
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%.
Earnings released on 13 Mar 2025
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%.
Earnings released on 12 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%.
Earnings released on 8 Aug 2024
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%.
Earnings released on 9 May 2024
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%.
Earnings released on 14 Mar 2024
EPS came in at -$0.21 falling short of the estimated -$0.16 by -31.25%, while revenue for the quarter reached $3.75m .
Earnings released on 9 Nov 2023
EPS came in at -$0.23 surpassing the estimated -$0.25 by +8.00%.
Earnings released on 10 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.28 by +3.57%.
Earnings released on 12 May 2023
EPS came in at -$0.30 surpassing the estimated -$0.33 by +9.09%.
Earnings released on 30 Mar 2023
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 10 Nov 2022
EPS came in at -$0.34 falling short of the estimated -$0.28 by -21.43%.
Earnings released on 12 Aug 2022
EPS came in at -$0.38 falling short of the estimated -$0.33 by -15.15%.
Earnings released on 12 May 2022
EPS came in at -$0.33 surpassing the estimated -$0.34 by +2.94%.
Earnings released on 17 Mar 2022
EPS came in at -$0.21 matching the estimated -$0.21.
Earnings released on 10 Nov 2021
EPS came in at -$0.25 surpassing the estimated -$0.33 by +24.24%.
Earnings released on 10 Sept 2021
EPS came in at -$0.16 surpassing the estimated -$0.30 by +45.79%.
Earnings released on 30 Jul 2021
EPS came in at -$0.16 .
INAB Stock Performance
Access detailed INAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
